Indian stocks: Visit www.stage2stocks.com →

Entera Bio Ltd.

Stage 2 · Advancing · week 12

As of Oct 22, 2026, Entera Bio is in Stage 2, the uptrend phase, now in week 12 (since Aug 3, 2026). It closed at $3.02, 23.0% below its 52-week high and above its 200-day average, which is rising.

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. More about the company

$3.02
-0.98% today
$525M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ENTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 13w
S2 21w
S4 21w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 13w → S1 5w → S4 3w → S1 4w → S2 21w → S3 12w → S2 8w → S4 4w → S1 3w → S2 9w → S3 6w → S4 4w → S1 4w → S2 4w → S1 1w → S4 12w → S1 2w → S2 9w → S3 4w → S4 21w → S1 6w → S2 12w current
Total tracked: 165 weeks across 22 stage runs.

ENTX among Biotechnology124th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…124ENTXStage 2 · wk 1274+7.5%
vs 52W High
-23.0%
$1.00 lo$3.92 hi
23.0% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 12
1w13w26w
Week 12, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
62.1%
200 DMA: $1.86 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.23x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+7.5%
3M
+47.3%
6M
+158.1%
YTD
+70.6%
1Y
+26.4%
Scan Membership
Breakout Watch
Latest: 2025-06-16
7 appearances in last 60 days. First seen: 2020-03-04.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 12 · Vol 1.23x
2026-10-21S2
Wk 12 · Vol 1.53x
2026-10-20S2
Wk 12 · Vol 1.57x
2026-10-19S2
Wk 11 · Vol 1.95x
2026-10-16S2
Wk 11 · Vol 1.18x
2026-10-15S2
Wk 11 · Vol 3.13x
2026-10-14S2
Wk 11 · Vol 1.69x
2026-10-13S2
Wk 11 · Vol 1.61x
2026-10-12S2
Wk 10 · Vol 0.63x
2026-10-09S2
Wk 10 · Vol 3.29x
2026-10-08S2
Wk 10 · Vol 0.83x
2026-10-07S2
Wk 10 · Vol 1.14x
Moving averages & range
50 DMA
$2.89
200 DMA
$1.86
52W High
$3.92
52W Low
$1.00
5D Low
$2.68
Resistance levels (recent highs)
20d High
$3.05
60d High
$3.47
120d High
$3.92
250d High
$3.92
Next resistance
+1.0%
to 20d High
ROE
-138.9%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 20.5

Entera Bio: quick answers

What stage is Entera Bio in?

As of Oct 22, 2026, Entera Bio (ENTX) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 3, 2026 and is in week 12. What the four stages mean

Is Entera Bio in an uptrend?

Yes. Entera Bio is in a Stage 2 uptrend. It trades 62.1% above its 200-day average, which is rising.

How far is Entera Bio from its 52-week high?

Entera Bio closed at $3.02 on Oct 22, 2026, 23.0% below its 52-week high of $3.92. Its 52-week low is $1.00.

How has Entera Bio performed over the past year?

As of Oct 22, 2026, Entera Bio is up 26.4% over the past year and up 70.6% so far in 2026.

Which sector and industry is Entera Bio in?

Entera Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.